Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
Discuss tips for understanding different motivating factors, how to leverage those factors, and how to recognize employees' positive energy and engagement.
Jane Hermansen, MT(ASCP), was recently featured in 360Dx discussing new federal regulations aimed at hospital price transparency.
This "Phlebotomy webinar" focuses on the origins of difficult collections and the situations that result in them.
This week’s research roundup features a study on the epidemiology, natural history, and optimal management of neurohypophyseal germ cell tumors.
In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., will discuss recent information on the advantages and disadvantages of using butterfly needles for blood collection.
In January 2020, Mayo Clinic Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.
At Mayo Clinic, we offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.
Divyanshu Dubey, M.B.B.S. gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
This week’s research roundup features a study on the impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain Amyloidosis.
Linda Baughn Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
Rondell Graham, M.B.B.S., an anatomic and molecular consultant at Mayo Clinic, co-led a molecular oncology tumor board session at CAP19, and subsequently spoke with CAP Today.
Elitza Theel, Ph.D., Director of the Infectious Diseases Serology Laboratory, Co-Director of the Vector-Borne Diseases Laboratory, and Associate Professor of Laboratory Medicine and Pathology, was recently interviewed by CAP Today about new Lyme disease testing.
Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff will be in Los Angeles, California, for the 109th United States and Canadian Academy of Pathology Meeting (USCAP). Visit us at booth #716 on March 2 - 4, 2020 to discuss how our testing can integrate with your practice.